Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 82

1.

Three Observations That Have Changed Our Understanding of Cyclin D1 and p27 in Cell Cycle Control.

Stacey DW.

Genes Cancer. 2010 Dec;1(12):1189-99. doi: 10.1177/1947601911403475.

2.

The checkpoint kinase ATM protects against stress-induced elevation of cyclin D1 and potential cell death in neurons.

Hitomi M, Stacey DW.

Cytometry A. 2010 Jun;77(6):524-33. doi: 10.1002/cyto.a.20885.

3.

Phosphorylation of cyclin D1 regulated by ATM or ATR controls cell cycle progression.

Hitomi M, Yang K, Stacey AW, Stacey DW.

Mol Cell Biol. 2008 Sep;28(17):5478-93. doi: 10.1128/MCB.02047-07. Epub 2008 Jul 7.

4.

Cell cycle studies based upon quantitative image analysis.

Stacey DW, Hitomi M.

Cytometry A. 2008 Apr;73(4):270-8. doi: 10.1002/cyto.a.20511. Review.

5.
6.

p27Kip1 and cyclin dependent kinase 2 regulate passage through the restriction point.

Hitomi M, Yang K, Guo Y, Fretthold J, Harwalkar J, Stacey DW.

Cell Cycle. 2006 Oct;5(19):2281-9. Epub 2006 Oct 1.

PMID:
16969133
7.

Glycogen synthase kinase 3 has a limited role in cell cycle regulation of cyclin D1 levels.

Yang K, Guo Y, Stacey WC, Harwalkar J, Fretthold J, Hitomi M, Stacey DW.

BMC Cell Biol. 2006 Aug 30;7:33.

8.

The regulation of S phase initiation by p27Kip1 in NIH3T3 cells.

Sa G, Guo Y, Stacey DW.

Cell Cycle. 2005 Apr;4(4):618-27. Epub 2005 Apr 25.

PMID:
15876875
9.

Phosphorylation of cyclin D1 at Thr 286 during S phase leads to its proteasomal degradation and allows efficient DNA synthesis.

Guo Y, Yang K, Harwalkar J, Nye JM, Mason DR, Garrett MD, Hitomi M, Stacey DW.

Oncogene. 2005 Apr 14;24(16):2599-612.

PMID:
15735756
10.

Destabilization of cyclin D1 message plays a critical role in cell cycle exit upon mitogen withdrawal.

Guo Y, Harwalkar J, Stacey DW, Hitomi M.

Oncogene. 2005 Feb 3;24(6):1032-42.

PMID:
15592507
11.
12.

Cyclin D1 serves as a cell cycle regulatory switch in actively proliferating cells.

Stacey DW.

Curr Opin Cell Biol. 2003 Apr;15(2):158-63. Review.

PMID:
12648671
13.

Ras is active throughout the cell cycle, but is able to induce cyclin D1 only during G2 phase.

Sa G, Hitomi M, Harwalkar J, Stacey AW, GC GC, Stacey DW.

Cell Cycle. 2002 Jan;1(1):50-8.

PMID:
12429909
14.

Post-transcriptional regulation of cyclin D1 expression during G2 phase.

Guo Y, Stacey DW, Hitomi M.

Oncogene. 2002 Oct 24;21(49):7545-56.

15.

Ras-dependent cell cycle commitment during G2 phase.

Hitomi M, Stacey DW.

FEBS Lett. 2001 Feb 16;490(3):123-31. Review.

16.
17.

The p38 pathway provides negative feedback for Ras proliferative signaling.

Chen G, Hitomi M, Han J, Stacey DW.

J Biol Chem. 2000 Dec 15;275(50):38973-80.

18.
19.
20.

Cell cycle arrest and morphological alterations following microinjection of NIH3T3 cells with Pur alpha.

Stacey DW, Hitomi M, Kanovsky M, Gan L, Johnson EM.

Oncogene. 1999 Jul 22;18(29):4254-61.

21.
22.

Adenovirus-mediated gene transfer of dominant negative Ha-Ras inhibits proliferation of primary meningioma cells.

Shu J, Lee JH, Harwalkar JA, Oh-Siskovic S, Stacey DW, Golubić M.

Neurosurgery. 1999 Mar;44(3):579-87; discussion 587-8.

PMID:
10069595
23.

p53 inhibits entry into mitosis when DNA synthesis is blocked.

Taylor WR, Agarwal ML, Agarwal A, Stacey DW, Stark GR.

Oncogene. 1999 Jan 14;18(2):283-95.

24.

p21Waf1 inhibits the activity of cyclin dependent kinase 2 by preventing its activating phosphorylation.

Hitomi M, Shu J, Agarwal M, Agarwal A, Stacey DW.

Oncogene. 1998 Aug 27;17(8):959-69.

25.
26.
27.

Neurofibromin colocalizes with mitochondria in cultured cells.

Roudebush M, Slabe T, Sundaram V, Hoppel CL, Golubic M, Stacey DW.

Exp Cell Res. 1997 Oct 10;236(1):161-72.

PMID:
9344596
28.

Reduced expression of schwannomin/merlin in human sporadic meningiomas.

Lee JH, Sundaram V, Stein DJ, Kinney SE, Stacey DW, Golubić M.

Neurosurgery. 1997 Mar;40(3):578-87.

PMID:
9055299
29.

Reduced expression of neurofibromin in human meningiomas.

Sundaram V, Lee JH, Harwalkar JA, Stein DJ, Roudebush M, Stacey DW, Golubic M.

Br J Cancer. 1997;76(6):747-56.

30.
31.

Prostaglandin A2 blocks the activation of G1 phase cyclin-dependent kinase without altering mitogen-activated protein kinase stimulation.

Hitomi M, Shu J, Strom D, Hiebert SW, Harter ML, Stacey DW.

J Biol Chem. 1996 Apr 19;271(16):9376-83.

32.

Transient blockage of proliferative signalling: a novel strategy for protective chemotherapy.

Weyman CM, Stacey DW.

Anticancer Res. 1996 Jan-Feb;16(1):493-8.

PMID:
8615661
33.
34.

The adenovirus E1A protein overrides the requirement for cellular ras in initiating DNA synthesis.

Stacey DW, Dobrowolski SF, Piotrkowski A, Harter ML.

EMBO J. 1994 Dec 15;13(24):6107-14.

35.

The regulation of endothelial cell motility by p21 ras.

Fox PL, Sa G, Dobrowolski SF, Stacey DW.

Oncogene. 1994 Dec;9(12):3519-26.

PMID:
7970712
36.

An E2F dominant negative mutant blocks E1A induced cell cycle progression.

Dobrowolski SF, Stacey DW, Harter ML, Stine JT, Hiebert SW.

Oncogene. 1994 Sep;9(9):2605-12.

PMID:
8058324
37.
38.

Functional role of GTPase-activating protein in cell transformation by pp60v-src.

DeClue JE, Vass WC, Johnson MR, Stacey DW, Lowy DR.

Mol Cell Biol. 1993 Nov;13(11):6799-809.

39.

Release from G1 growth arrest by transforming growth factor beta 1 requires cellular ras activity.

Howe PH, Dobrowolski SF, Reddy KB, Stacey DW.

J Biol Chem. 1993 Oct 5;268(28):21448-52.

40.
41.
42.

Catalytic properties, tissue and intracellular distribution of neurofibromin.

Golubić M, Roudebush M, Dobrowolski S, Wolfman A, Stacey DW.

Oncogene. 1992 Nov;7(11):2151-9.

PMID:
1437143
43.

Dominant inhibitory Ras mutants demonstrate the requirement for Ras activity in the action of tyrosine kinase oncogenes.

Stacey DW, Roudebush M, Day R, Mosser SD, Gibbs JB, Feig LA.

Oncogene. 1991 Dec;6(12):2297-304.

PMID:
1766676
44.

The GTPase stimulatory activities of the neurofibromatosis type 1 and the yeast IRA2 proteins are inhibited by arachidonic acid.

Golubić M, Tanaka K, Dobrowolski S, Wood D, Tsai MH, Marshall M, Tamanoi F, Stacey DW.

EMBO J. 1991 Oct;10(10):2897-903.

45.
46.

Ras GTPase-activating protein physically associates with mitogenically active phospholipids.

Tsai MH, Roudebush M, Dobrowolski S, Yu CL, Gibbs JB, Stacey DW.

Mol Cell Biol. 1991 May;11(5):2785-93.

47.

Preferential inhibition of the oncogenic form of RasH by mutations in the GAP binding/"effector" domain.

Farnsworth CL, Marshall MS, Gibbs JB, Stacey DW, Feig LA.

Cell. 1991 Feb 8;64(3):625-33.

PMID:
1899358
48.
49.

A cytoplasmic protein inhibits the GTPase activity of H-Ras in a phospholipid-dependent manner.

Tsai MH, Yu CL, Stacey DW.

Science. 1990 Nov 16;250(4983):982-5.

PMID:
2237442
50.

Supplemental Content

Loading ...
Support Center